All In Biotech

Drug Trial Radar · NCT04590586

Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients

Industry Alliance Platform Trial to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients

Last checked: Nov 20, 2026Latest source record: Jun 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 515 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

515

Actual

Start

Nov 24, 2020

Primary completion

Aug 3, 2021

Study completion Aug 3, 2021

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Oct 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the time to confirmed clinical recovery in participants hospitalized with COVID-19. Candidate agents will be evaluated frequently for efficacy and safety, with candidate agents being added to and/or removed from the study on an ongoing basis, depending on the results of their evaluation.

Conditions

  • COVID-19

Interventions

  • Standard of careDrug

    Standard of care (SoC) treatment for COVID-19 infection in line with institutional practice. The SoC may change as new information becomes available about treating COVID-19.

  • ApremilastDrug

    Apremilast administered orally as a tablet.

  • Apremilast placeboDrug

    Matching apremilast placebo administered orally as a tablet.

  • LanadelumabDrug

    Lanadelumab administered as an intravenous (IV) infusion.

  • Lanadelumab placeboDrug

    Matching lanadelumab placebo (normal saline) administered as an intravenous (IV) infusion.

  • ZilucoplanDrug

    Zilucoplan administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.

  • Zilucoplan placeboDrug

    Matching zilucoplan placebo administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Lanadelumab Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29Time frame: Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29
  2. Apremilast Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29Time frame: Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29
  3. Zilucoplan Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29Time frame: Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29

Locations

59 sites in 8 countries. Site status is shown where the registry gives one.

  • Pinnacle Research Group LLC

    Anniston, Alabama

  • Good Samaritan Hospital

    Bakersfield, California

  • Sharp Chula Vista Medical Center

    Chula Vista, California

  • El Centro Regional Medical Center

    El Centro, California

  • University of California Irvine Medical Center

    Orange, California

  • Riverside Community Hospital

    Riverside, California

  • University of California Davis Health System

    Sacramento, California

  • National Institute of Clinical Research

    South El Monte, California

  • UF Health Shands Hospital

    Gainesville, Florida

  • Memorial Hospital Jacksonville

    Jacksonville, Florida

  • Grady Health System

    Atlanta, Georgia

  • Great Lakes Clinical Trials

    Chicago, Illinois

  • The University of Iowa

    Iowa City, Iowa

  • Harper University Hospital

    Detroit, Michigan

  • Sinai Grace Hospital

    Detroit, Michigan

  • Detroit Receiving Hospital

    Royal Oak, Michigan

  • University of Tennessee Health Sciences Center

    Memphis, Tennessee

  • Medical City Ft. Worth

    Fort Worth, Texas

  • University of Texas Health Science Center at Houston

    Houston, Texas

  • Texoma Medical Center

    Sherman, Texas

  • MultiCare Health System Institute for Research and Innovation

    Tacoma, Washington

  • Hospital General de Agudos Dr. J. M. Ramos Mejia

    Ciudad Autonoma Buenos Aires, Argentina

  • Hospital General de Agudos Dr. Ignacio Pirovano

    Ciudad Autonoma Buenos Aires, Argentina

  • Clinica Adventista Belgrano

    Ciudad Autonoma Buenos Aires, Argentina

  • Hospital Italiano de Rosario

    Rosario, Argentina

  • Hospital San Juan de Dios

    Ramos Mejía, Buenos Aires, Argentina

  • Chronos Pesquisa Clinica

    Brasília, Federal District, Brazil

  • HC-UFG - Hospital das Clínicas da Universidade Federal de Goiás

    Goiânia, Goiás, Brazil

  • Santa Casa de Misericórdia de Belo Horizonte

    Belo Horizonte, Minas Gerais, Brazil

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu

    Botucatu, São Paulo, Brazil

  • Praxis Pesquisa Médica

    Santo André, São Paulo, Brazil

  • Hospital Base Osorno

    Osorno, Chile

  • Hospital General de Tijuana

    Tijuana, Baja California Norte, Mexico

  • Hospital Civil de Guadalajara Dr. Juan I. Menchaca

    Guadalajara, Jalisco, Mexico

  • Universidad Autonoma de Nuevo Leon, Hospital Universitario Dr. Jose Eleuterio Gonzalez

    Monterrey, Nuevo León, Mexico

  • Hospital Civil de Culiacan

    Culiacán, Sinaloa, Mexico

  • TSBIH "Krasnoyarsk Interdistrict Clinical Hospital of Emergency Medical Care n.a. N.S. Karpovich

    Krasnoyarsk, Russia

  • SBIH of Moscow "Infectious Clinical Hospital # 1 of Department of Healthcare of Moscow"

    Moscow, Russia

  • SPb SBIH "Alexandrovskaya City Hospital"

    Saint Petersburg, Russia

Showing 40 of 59 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.